Unknown PHASE1 INTERVENTIONAL 2-arm NCT03570346

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

A Randomised, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Hemay005 in Healthy Subjects

Sponsor: Tianjin Hemay Bio-Tech Co., Ltd

Conditions Psoriasis

Interventions Hemay005 Placebo

Updated 6 times since 2018 Last updated: Sep 29, 2018 Started: Jul 10, 2018 Primary completion: Oct 20, 2018 Completion: Dec 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Psoriasis, this trial is ongoing. The trial is conducted by Tianjin Hemay Bio-Tech Co., Ltd and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Nov 2018 — Jul 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jul 2018 — Nov 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Hemay Bio-Tech Co., Ltd

Data source: Tianjin Hemay Bio-Tech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China